Jazz Pharmaceuticals, Inc. (JAZZ) is a publicly traded Healthcare sector company. As of July 17, 2026, JAZZ trades at $237.63 with a market cap of $15.03B and a P/E ratio of 26.74. JAZZ moved -1.88% today. Year to date, JAZZ is +42.46%; over the trailing twelve months it is +108.63%. Its 52-week range spans $95.49 to $250.49. Analyst consensus is strong buy with an average price target of $259.87. Rallies surfaces JAZZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for JAZZ, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $237.63 |
| Market Cap | $15.03B |
| P/E Ratio | 26.74 |
| EPS | $9.06 |
| Dividend Yield | 0.00% |
| 52-Week High | $250.49 |
| 52-Week Low | $95.49 |
| Volume | 4 |
| Avg Volume | 0 |
| Revenue (TTM) | $4.07B |
| Net Income | $560.12M |
| Gross Margin | 0.00% |
17 analysts cover JAZZ: 0 strong buy, 16 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $259.87.